A clinical study on Siddha trial drug Nilavagai choornam in children having Sirangu.

An open clinical study on Sirangu (Scabies) in children with the evaluation of Siddha trial drug nilavagai chooranam(int) and Sirangu thylam(ext).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/09/015605

Enrollment

Registered

2018-09-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Interventions

Intervention1: Nilavagai chooranam(internal) and sirangu thylam (external): 500mg with hot water/ghee twice a day for 21 days as internal medicine Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Nocturnal itching Burrows Papules and papulovesicle Pustules Lesion seen in wrist, web of hands,buttocks

Exclusion criteria

Exclusion criteria: Eczema Foliculitis Seborrheic dermatitis Insect bites Psoriasis

Design outcomes

Primary

Measure	Time frame
Reducing in clinical symptoms like itching and burrow Reduction pustules in affected area To evaluate the days of outcome with in the treatment of 28 daysTimepoint: Nil	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameters before and after treatmentTimepoint: Nil	—

Countries

India

Contacts

Public ContactE K Murugan

Government Siddha medical college

dr.shanmugapriyaa.km@gmail.com9445661808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026